• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

16例严重原发性体液免疫缺陷患者静脉注射丙种球蛋白治疗期间IgG半衰期和清除率的变化

Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.

作者信息

Schiff R I, Rudd C

出版信息

J Clin Immunol. 1986 May;6(3):256-64. doi: 10.1007/BF00918706.

DOI:10.1007/BF00918706
PMID:2424931
Abstract

Published studies of the metabolism of human IgG using trace amounts of radiolabeled IgG demonstrated that the elimination of native IgG followed first-order kinetics but that the half-life of IgG was shortest in patients with the highest serum concentrations of IgG. To evaluate the effect of increasing the serum concentration of IgG on the metabolism of IgG, we determined the half-life and clearance of IgG and tetanus antibody in 16 patients with severe primary humoral immunodeficiency diseases while they received several doses of intravenous gamma-globulin (IVIG). Each patient received 100 mg/kg of IVIG each month and the half-life and clearance of IVIG were determined by following the decline in the serum IgG concentration. The dose of IVIG was adjusted to give a minimum IgG level of 200 mg/dl and the half-life was reevaluated. The dose was again adjusted to give minimum concentrations of 450 mg/dl and two additional studies were performed. Mean doses of IVIG infused increased from 100 to 346 mg/kg. The mean trough serum IgG concentration was 191 mg/dl on the standard dose and increased to 427 mg/dl at the highest dose. The serum half-lives of IgG were highly variable, ranging from 22 to 96 days. The mean decreased from 43 days in the first to 33 days in the third and fourth studies, and the clearances of IgG increased from 1.8339 to 2.4302 mg/kg/day, but the differences were not statistically significant. Patients with the highest serum IgG concentrations tended to have the longest half-lives, suggesting that intrinsic IgG production might falsely prolong the calculated half-life of IgG.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

已发表的关于使用微量放射性标记 IgG 研究人 IgG 代谢的研究表明,天然 IgG 的消除遵循一级动力学,但在血清 IgG 浓度最高的患者中,IgG 的半衰期最短。为了评估增加血清 IgG 浓度对 IgG 代谢的影响,我们在 16 例严重原发性体液免疫缺陷疾病患者接受几剂静脉注射丙种球蛋白(IVIG)时,测定了 IgG 和破伤风抗体的半衰期及清除率。每位患者每月接受 100 mg/kg 的 IVIG,通过跟踪血清 IgG 浓度的下降来测定 IVIG 的半衰期和清除率。调整 IVIG 的剂量以使 IgG 最低水平达到 200 mg/dl,并重新评估半衰期。再次调整剂量以使最低浓度达到 450 mg/dl,并进行另外两项研究。注入的 IVIG 平均剂量从 100 mg/kg 增加到 346 mg/kg。标准剂量时血清 IgG 平均谷浓度为 191 mg/dl,最高剂量时增至 427 mg/dl。IgG 的血清半衰期变化很大,范围从 22 天到 96 天。平均值从第一项研究中的 43 天降至第三项和第四项研究中的 33 天,IgG 的清除率从 1.8339 mg/kg/天增加到 2.4302 mg/kg/天,但差异无统计学意义。血清 IgG 浓度最高的患者往往半衰期最长,这表明内源性 IgG 产生可能会错误地延长计算出的 IgG 半衰期。(摘要截短于 250 字)

相似文献

1
Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.16例严重原发性体液免疫缺陷患者静脉注射丙种球蛋白治疗期间IgG半衰期和清除率的变化
J Clin Immunol. 1986 May;6(3):256-64. doi: 10.1007/BF00918706.
2
Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency.个体化静脉注射免疫球蛋白剂量用于原发性体液免疫缺陷患者的治疗
Vox Sang. 1985;49 Suppl 1:15-24. doi: 10.1111/j.1423-0410.1985.tb01139.x.
3
Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.一种新型化学修饰的静脉注射免疫球蛋白制剂在严重原发性体液免疫缺陷中的应用:临床疗效及个体化剂量尝试
Clin Immunol Immunopathol. 1984 Apr;31(1):13-23. doi: 10.1016/0090-1229(84)90185-5.
4
Individualization of gamma globulin dosage in patients with humoral immunodeficiency.体液免疫缺陷患者丙种球蛋白剂量的个体化
Birth Defects Orig Artic Ser. 1983;19(3):209-12.
5
The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.接受静脉注射免疫球蛋白的原发性免疫缺陷患者中IgG亚类和特异性抗体的半衰期。
J Lab Clin Med. 1988 Nov;112(5):634-40.
6
Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.
Rev Infect Dis. 1986 Jul-Aug;8 Suppl 4:S449-56. doi: 10.1093/clinids/8.supplement_4.s449.
7
Build-up maintenance of IgG serum concentrations with intravenous immunoglobulin in patients with primary humoral immunodeficiency.
Vox Sang. 1982;43(4):212-9. doi: 10.1111/j.1423-0410.1982.tb00014.x.
8
Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.静脉注射免疫球蛋白在原发性体液免疫缺陷病中的疗效。
Ann Intern Med. 1984 Oct;101(4):435-9. doi: 10.7326/0003-4819-101-4-435.
9
Clinical uses of intravenous immune globulin: immunoglobulin replacement therapy and treatment of autoimmune cytopenias.静脉注射免疫球蛋白的临床应用:免疫球蛋白替代疗法及自身免疫性血细胞减少症的治疗。
J Clin Apher. 1988;4(2-3):97-103. doi: 10.1002/jca.2920040212.
10
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.评估皮下免疫球蛋白替代疗法中剂量与临床结局的相关性。
Clin Exp Immunol. 2012 Aug;169(2):172-81. doi: 10.1111/j.1365-2249.2012.04594.x.

引用本文的文献

1
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.原发性免疫缺陷病的免疫球蛋白治疗(第 1 部分):了解药代动力学。
Immunotherapy. 2024;16(13):879-894. doi: 10.1080/1750743X.2024.2382081. Epub 2024 Sep 26.
2
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.大剂量透明质酸酶辅助皮下注射10%免疫球蛋白的耐受性和安全性:有无剂量递增的1期健康受试者研究
J Clin Immunol. 2024 Jun 19;44(7):148. doi: 10.1007/s10875-024-01742-5.
3
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.

本文引用的文献

1
[GAMMA GLOBULIN METABOLISM IN AGAMMAGLOBULINEMIA AND HYPOGAMMAGLOBULINEMIA. STUDY OF TURNOVER WITH GAMMA GLOBULIN-I-131].[无丙种球蛋白血症和低丙种球蛋白血症中的γ球蛋白代谢。用γ球蛋白-I-131研究周转率]
Helv Med Acta. 1964 Nov;31:618-22.
2
EVIDENCE FOR SPECIES' DIFFERENCES IN THE EFFECT OF SERUM GAMMA-GLOBULIN CONCENTRATION ON GAMMA-GLOBULIN CATABOLISM.血清γ球蛋白浓度对γ球蛋白分解代谢影响中物种差异的证据。
J Exp Med. 1964 Nov 1;120(5):967-86. doi: 10.1084/jem.120.5.967.
3
FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.控制血清γ-球蛋白浓度的因素。
体重和年龄对原发性免疫缺陷病患者皮下或透明质酸酶辅助皮下免疫球蛋白 G 药代动力学的影响。
J Clin Immunol. 2023 Nov;43(8):2127-2135. doi: 10.1007/s10875-023-01572-x. Epub 2023 Sep 29.
4
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.针对 GD2 的 IgA 抗体免疫疗法在神经母细胞瘤的临床前模型中有效。
J Immunother Cancer. 2023 Jul;11(7). doi: 10.1136/jitc-2023-006948.
5
Characterization of the primary antibody response to Plasmodium falciparum antigens in infants living in a malaria-endemic area.在疟疾流行地区生活的婴儿中,对疟原虫抗原的初始抗体反应的特征。
Malar J. 2022 Nov 19;21(1):346. doi: 10.1186/s12936-022-04360-x.
6
Misleading Positive Serology for Cat Scratch Disease following Administration of Intravenous Immunoglobulin.静脉注射免疫球蛋白后猫抓病血清学假阳性
Pathogens. 2022 Jan 27;11(2):177. doi: 10.3390/pathogens11020177.
7
In Translation: FcRn across the Therapeutic Spectrum.在治疗谱中:FcRn。
Int J Mol Sci. 2021 Mar 17;22(6):3048. doi: 10.3390/ijms22063048.
8
Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence.基于药代动力学证据优化免疫球蛋白剂量的考量
Antibodies (Basel). 2020 Jun 19;9(2):24. doi: 10.3390/antib9020024.
9
Treatment of Pediatric Acute-Onset Neuropsychiatric Disorder in a Large Survey Population.在一大群调查对象中对儿童急性起病神经精神障碍的治疗
J Child Adolesc Psychopharmacol. 2018 Mar;28(2):92-103. doi: 10.1089/cap.2017.0101. Epub 2017 Aug 23.
10
Immunoglobulin replacement therapy in children.儿童免疫球蛋白替代疗法
Immunol Allergy Clin North Am. 2008 Nov;28(4):833-49, ix. doi: 10.1016/j.iac.2008.07.001.
J Exp Med. 1963 Nov 1;118(5):845-68. doi: 10.1084/jem.118.5.845.
4
Individual patient variations in the kinetics of intravenous immune globulin administration.静脉注射免疫球蛋白给药动力学的个体患者差异。
J Clin Immunol. 1982 Apr;2(2 Suppl):7S-14S. doi: 10.1007/BF00918361.
5
Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial.静脉注射丙种球蛋白在抗体免疫缺陷中的应用:一项多中心对照试验的结果
Clin Immunol Immunopathol. 1982 Jan;22(1):60-7. doi: 10.1016/0090-1229(82)90022-8.
6
Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases.
Am J Med. 1984 Mar 30;76(3A):78-82. doi: 10.1016/0002-9343(84)90324-3.
7
Intravenous immune globulin therapy in hypogammaglobulinemia. A review.低丙种球蛋白血症的静脉注射免疫球蛋白治疗。综述。
Am J Med. 1984 Mar 30;76(3A):53-60. doi: 10.1016/0002-9343(84)90320-6.
8
Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.一种新型化学修饰的静脉注射免疫球蛋白制剂在严重原发性体液免疫缺陷中的应用:临床疗效及个体化剂量尝试
Clin Immunol Immunopathol. 1984 Apr;31(1):13-23. doi: 10.1016/0090-1229(84)90185-5.
9
In vivo behaviour of gamma globulin preparations.γ球蛋白制剂的体内行为。
Vox Sang. 1980;38(5):272-83. doi: 10.1111/j.1423-0410.1980.tb02367.x.
10
Survival studies on a commercial preparation of intravenous human gammaglobulin labelled with 131-I.
Australas Ann Med. 1969 Aug;18(3):271-6. doi: 10.1111/imj.1969.18.3.271.